Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemiasDivergencia entre las guías europea y estadounidense

  1. José María Lobos Bejarano 2
  2. Enrique Galve 1
  3. Miguel Ángel Royo-Bordonada 2
  4. Eduardo Alegría Ezquerra 1
  5. Pedro Armario 2
  6. Carlos Brotons Cuixart 2
  7. Miguel Camafort Babkowski 2
  8. Alberto Cordero Fort 1
  9. Antonio Maiques Galán 2
  10. Teresa Mantilla Morató 3
  11. Antonio Pérez Pérez 2
  12. Juan Pedro-Botet 4
  13. Fernando Villar Álvarez 2
  14. José Ramón González-Juanatey 1
  1. 1 Sociedad Española de Cardiología, Madrid
  2. 2 Comité Español Interdisciplinario de Prevención Cardiovascular
  3. 3 Sociedad Española de Medicina de Familia y Comunitaria, Madrid
  4. 4 Sociedad Española de Arteriosclerosis, Madrid
Show affiliations +
Journal:
Hipertensión y riesgo vascular

ISSN: 1889-1837

Year of publication: 2015

Volume: 32

Issue: 2

Pages: 83-91

Type: Article

DOI: 10.1016/J.HIPERT.2014.09.002 DIALNET GOOGLE SCHOLAR

More publications in: Hipertensión y riesgo vascular

Abstract

The publication of the 2013 American College of Cardiology/American Heart Association guidelines on the treatment of high blood cholesterol has had a strong impact due to the paradigm shift in its recommendations. The Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology reviewed this guideline and compared it with current European guidelines on cardiovascular prevention and dyslipidemia management. The most striking aspect of the American guideline is the elimination of the low-density lipoprotein cholesterol treat-to-target strategy and the adoption of a risk reduction strategy in 4 major statin benefit groups. In patients with established cardiovascular disease, both guidelines recommend a similar therapeutic strategy (high-dose potent statins). However, in primary prevention, the application of the American guidelines would substantially increase the number of persons, particularly older people, receiving statin therapy. The elimination of the cholesterol treat-to-target strategy, so strongly rooted in the scientific community, could have a negative impact on clinical practice, create a certain amount of confusion and uncertainty among professionals, and decrease follow-up and patient adherence. Thus, this article reaffirms the recommendations of the European guidelines. Although both guidelines have positive aspects, doubt remains regarding the concerns outlined above. In addition to using risk charts based on the native population, the messages of the European guideline are more appropriate to the Spanish setting and avoid the possible risk of overtreatment with statins in primary prevention.

Data source: Dialnet